retatrutide triple agonist glp-1 gip glucagon LY3437943, a novel glucagon, GIP, and receptor for glycemic control and weight loss: From discovery to clinical proof of concept YouTube

Some of the nations top obesity medicine specialists helped design our program

The absence of a control group precludes definitive conclusions on causality between GLP-1 receptor agonist therapy and observed outcomes, and residual confounding cannot be excluded In conclusion, arGLP-1 represent a valuable addition to the therapeutic arsenal for managing IWL or WR after BS

Therefore, overall, the benefit of GLP-1RAs for heart failure has been difficult to confirm (Figure 1)

5) GLP-1

[cited 2025 Feb 1]

Consequently, GLP-1RAs are recommended as a first-line injectable therapy for patients requiring pharmacological intervention to achieve glycemic control [7]